Ethnic Differences in the Management of Lung Cancer in New Zealand

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.

Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia Arman Hasani, MBBS, FRACP, John M. Alvarez,

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD

A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.

Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer Eiko Theodora Browning, MD, Andrew James.

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Pleural Well-Differentiated Papillary Mesothelioma: A Case Report

Electronic Updates for JTO Readers

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer W Jeffrey Petty, MD, Sommer N.

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Michelle C. Ellis, MD, Brian S. Diggs, PhD, John T. Vetto, MD, Paul H

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

Frank Detterbeck, MD Journal of Thoracic Oncology

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Bilateral Patellar Metastases from Non-small Cell Lung Cancer

Timeliness Across the Continuum of Care in Veterans with Lung Cancer

Prevention and Management of Bone Metastases in Lung Cancer: A Review

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 Paul J. Hesketh, MD, Rogerio C. Lilenbaum,

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Ann G. Schwartz, PhD, Michele L. Cote, PhD, Angela S

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Mitotic Inhibitors Journal of Thoracic Oncology

A Translational View of the Molecular Pathogenesis of Lung Cancer

Ayman O. Soubani, MD, John C. Ruckdeschel, MD

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy Yelena.

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

Long-Term Results of a Phase II Trial of Induction Paclitaxel-Carboplatin Followed by Concurrent Radiation Therapy and Weekly Paclitaxel and Consolidation.

A Critique of the International Association for the Study of Lung Cancer Lymph Node Map: A Radiation Oncology Perspective Graham Pitson, MBBS, FRANZCR,

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Gaps in Optimal Care for Lung Cancer

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Genetic Changes in Squamous Cell Lung Cancer: A Review

Bronchoepidural Fistula in a Man with Actinomycosis Complicated Non-small Cell Lung Cancer Mun Sem Liew, MBBS, BMedSci, Surein Arulananda, MBBS, BMedSci,

European Lung Cancer Conference (ELCC) 2016 Organisation

Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer Judith Elizabeth Carser, MB, BCh, MRCR, Yvonne Jane Summers,

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

A Pathological Complete Response in Malignant Pleural Mesothelioma after Combination Chemotherapy with Carboplatin and Pemetrexed Steven Chuan-Hao Kao,

Lung Cancer in New Zealand: Patterns of Secondary Care and Implications for Survival Wendy Stevens, MBBS, Graham Stevens, MD, FRANZCR, John Kolbe, MBBS,

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Tumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer

Annemarie Becker, MD, PhD, Atie van Wijk, RN, Egbert F

Impact of Information on Quality of Life and Satisfaction of Non-small Cell Lung Cancer Patients: A Randomized Study of Standardized versus Individualized.

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non- small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

A Review of First-Line Treatment for Small-cell Lung Cancer

Mark A. Socinski, MD Journal of Thoracic Oncology

Elevated Preoperative C-reactive Protein Predicts Poor Cancer Specific Survival in Patients Undergoing Resection for Non-small Cell Lung Cancer Caroline.

Robert Comis, MD, The Passing of a “Lung Man”

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Node-Negative Non-small Cell Lung Cancer: Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy,

Presentation transcript:

Ethnic Differences in the Management of Lung Cancer in New Zealand Wendy Stevens, MBBS, DipGrad, Graham Stevens, MD, FRANZCR, John Kolbe, MBBS, FRACP, Brian Cox, MBChB, PhD, FAFPHM Journal of Thoracic Oncology Volume 3, Issue 3, Pages 237-244 (March 2008) DOI: 10.1097/JTO.0b013e3181653d08 Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Stage of non-small cell lung cancer at diagnosis by ethnicity. Journal of Thoracic Oncology 2008 3, 237-244DOI: (10.1097/JTO.0b013e3181653d08) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Type of management received by ethnicity. Journal of Thoracic Oncology 2008 3, 237-244DOI: (10.1097/JTO.0b013e3181653d08) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions